BOULDER, Colo., Oct. 29, 2014 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) will report financial results for the first quarter of fiscal 2015 and hold a conference call to discuss those results on Tuesday, November 4, 2014. Ron Squarer, Chief Executive Officer and Michael Carruthers, Chief Financial Officer will lead the call.



    Date:                                              Tuesday, November 4, 2014

    Time:                                              9:00 a.m. Eastern Time

    Toll-Free:                                         (800) 708-4540

    Toll:                                              (847) 619-6397

    Pass Code:                                                                   38177000

    Webcast, including Replay and Conference Call Slides:

    http://www.media-server.com/m/acs/835a9ca60ab7df8747dc3aa3ad1d878b

About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Seven Phase 3 studies are in progress, or are planned to begin this year. These programs include the wholly-owned hematology drug, filanesib (ARRY-520) for multiple myeloma and two partnered cancer drugs, selumetinib (AstraZeneca) and binimetinib (MEK162 / Novartis). For more information on Array, please go to www.arraybiopharma.com.



    CONTACT:                          Tricia Haugeto

                                      Array BioPharma Inc.

                                      (303) 386-1193

                                      thaugeto@arraybiopharma.com

SOURCE Array BioPharma